| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0248-8663(03)00109-7 |
| P698 | PubMed publication ID | 14736559 |
| P2093 | author name string | Y Gruel | |
| P2860 | cites work | Heparin-associated thrombocytopenia syndrome: an underestimated etiology of adrenal hemorrhage | Q33493460 |
| Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia | Q33494985 | ||
| Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia | Q33495595 | ||
| A 14-year study of heparin-induced thrombocytopenia | Q33497877 | ||
| A fatal low-molecular-weight heparin-associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin ELISA test. | Q33497958 | ||
| A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry | Q33498117 | ||
| Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin. | Q33498474 | ||
| Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery | Q33498612 | ||
| The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia | Q33500949 | ||
| Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. | Q33501187 | ||
| Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. | Q33502010 | ||
| High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery | Q33503096 | ||
| Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study | Q33504870 | ||
| Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation | Q42579782 | ||
| Thrombocytopenia associated with low-molecular-weight heparin | Q45822676 | ||
| Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis | Q63101860 | ||
| Heparin-induced skin lesions | Q71005116 | ||
| Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis | Q28334344 | ||
| Heparin-induced thrombocytopenia: a ten-year retrospective | Q28371288 | ||
| Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia | Q28374015 | ||
| Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban | Q31930059 | ||
| Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia | Q32110828 | ||
| Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia | Q33328699 | ||
| Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. | Q33328813 | ||
| Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia | Q33329275 | ||
| Venous thromboembolism in heparin-induced thrombocytopenia | Q33333280 | ||
| Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease | Q33334613 | ||
| Recombinant hirudin in clinical practice: focus on lepirudin. | Q33336308 | ||
| Temporal aspects of heparin-induced thrombocytopenia | Q33337021 | ||
| Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. | Q33337245 | ||
| Delayed-onset heparin-induced thrombocytopenia and thrombosis | Q33339103 | ||
| Platelet activation induced by human antibodies to interleukin-8. | Q33344855 | ||
| The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study | Q33345667 | ||
| Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia | Q33345893 | ||
| Intraoperative management of patients with heparin-induced thrombocytopenia | Q33372350 | ||
| Immune endothelial-cell injury in heparin-associated thrombocytopenia | Q33456857 | ||
| Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospectively in vitro selected heparinoid (ORG 10172) | Q33489262 | ||
| Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin | Q33489438 | ||
| Transient global amnesia associated with acute heparin-induced thrombocytopenia | Q33491283 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | French | Q150 |
| P921 | main subject | pathogenesis | Q372016 |
| thrombocytopenia | Q585285 | ||
| P304 | page(s) | 35-45 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Revue de Médecine Interne | Q3428665 |
| P1476 | title | Heparin-induced thrombocytopenia. Pathogenesis, diagnosis and treatment | |
| P478 | volume | 25 |
| Q33392031 | Assessment of the interest of using confirmatory test in ELISA with use of high concentration of heparin-induced thrombocytopenia |
| Q33367960 | Does antiaggregant therapy have a place in type II heparin-induced thrombocytopenia? |
| Q33379953 | Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in France |
| Q33397508 | Post-traumatic pulmonary embolism in the intensive care unit |
| Q30802486 | [Optimizing history taking for evaluating the risk of venous thromboembolism: the OPTIMEV study]. |
Search more.